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The risk of respiratory disease in the transported horse can increase as a consequence
of immunosuppression and stress associated primarily with opportunistic bacterial
proliferation and viral reactivation. This study examines the ecology of equid
herpesviruses (EHV) in these horses, exploring reactivation and changes in infection
and shedding associated with transport, and any potential contributions to transport-
related respiratory disease. Twelve horses were subjected to an 8-h road-transport
event. Antibodies to EHV-1 and EHV-4 were detected by ELISA in serum collected
prior to, immediately after and 2 weeks post transport. Respiratory tract endoscopy
and tracheal washes were collected prior to and 5 days after transportation. Nasal
swabs collected prior to, immediately after, 1 and 5 days following transport were
screened for EHV-1,-2,-4,-5 using qPCR. Six horses had persistent neutrophilic airway
infiltrates post transportation, indicative of subclinical respiratory disease. No horses
were qPCR positive for either of the alphaherpesviruses (i.e., EHV-1/-4) nor did any
seroconvert to either virus. Four out of nine horses positive for either EHV-2 or
EHV-5 on qPCR prior to transport developed neutrophilic airway inflammation. Five
horses showed increasingly positive readings on qPCR (i.e., reduced Cq) for EHV-2
after transportation and seven out of eleven horses positive for EHV-2 after transport
shared strains of high sequence similarity with other horses in the study. One EHV-
2 virus detected in one horse after transport was genetically different which may
be due to reactivation. The clinical significance of EHV-2 and EHV-5 remains in
question. However these results indicate that transportation may lead to increased
shedding, transmission and reactivation of EHV-2 and EHV-5 but not EHV-1/-4. Unlike
previous work focusing on the role of alphaherpesviruses, this research suggests that
investigation of the gammaherpesviruses (i.e., EHV-2/-5) in transport-related disease
should not be dismissed, particularly given that these viruses can encode suppressive
immunomodulators that may affect host health.
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INTRODUCTION
Respiratory disease is a significant economic problem for the
equine industry, disrupting performance and training of athletic
horses and producing outbreaks of contagious illness in herds
that can result in mortalities of foals and adult horses (1). The
equine alphaherpesviruses, equid herpesvirus 1 (EHV-1) and
EHV-4 are among the most well-known and well-characterized
of the respiratory viruses to affect horse populations, notorious
for producing severe clinical signs of upper respiratory tract
disease in naïve horses (2). EHV-1 produces systemic infections,
with strains associated with abortion and neurological disease
(3). Although more prevalent, the contribution of EHV-
2 and EHV-5 to disease is less defined. These viruses are
predominantly found in normal horses, however, infections
have been associated with both mild and severe respiratory
illness and occasionally with other non-respiratory cases (4–
8). Nevertheless, gammaherpesviruses have immunomodulation
capacity in the host that could potentially increase susceptibility
to secondary pathogens with more severe disease outcomes
(9–12).
As members of the family Herpesviridae these viruses are
characterized by their ability to establish latent infections within
the host, a period of limited gene expression followed by
reactivation of viral shedding and/or recrudescent manifestation
of disease (13). Like other alphaherpesviruses EHV-1 and EHV-
4 establish latency in neural cells, specifically within neurons
in the trigeminal ganglia and in cells of the lymphoreticular
system (14). Gammaherpesviruses on the other hand prefer
to establish latency in cells of the immune system such as
B-lymphocytes in the case of EHV-2 and EHV-5 (15–17).
Reactivation of latent infections with subsequent viral shedding
has been observed naturally after stress-inducing events and has
also been achieved experimentally through administration of
corticosteroids (18, 19).
Transport-associated respiratory disease in the horse is
primarily associated with compromise of the respiratory tract
mucociliary clearance system on account of the need to maintain
the horse in an upright position with restricted movement of the
head. This physiological restriction, allows commensal bacteria
of the upper respiratory tract to migrate down to the lungs and
establish pneumonia in an opportunistic fashion (20). However,
immunosuppression due to stress may also be a contributing
factor in equine transport-related disease. Previous research has
associated increased shedding of the alphaherpesviruses with
long distance transportation. Reactivation of latent herpesviruses
due to transport stress has also been suggested (21). The current
study is unique in its aim to use serological and nucleic acid
based techniques to identify evidence of recrudescence, potential
transmission and changes in shedding of EHV-1,-2,-4, and-
5 in horses following a long distance transport event, and
assess the potential role of these common respiratory viruses
in transportation associated respiratory disease syndromes in
horses. It is hypothesized that transport stress will stimulate
viral shedding and reactivation of previously latent herpesvirus
infections and potentially increase susceptibility of horses to
respiratory disease.
MATERIALS AND METHODS
Equine Population and Transport Event
Twelve horses between 3 and 8 years old [Standardbreds (n =
8) and Thoroughbreds (n = 4)] were purchased for the study,
including mares (n = 5) and geldings (n = 7). Horses were
divided into 2 groups of 6 and transported on a truck on two
separate, consecutive days. The horses were transported for 8 h
in basically a single loop around the Riverina region of New
South Wales. The trip was punctuated by one 15-min period of
rest midway through the trip, in accordance with Animal Ethics
requirements (ACEC 14/037). Vaccination and transport history
was unknown with the exception of the transfer of all study
animals from the same owner 3 weeks prior to the experiment.
Animals were mixed within a paddock over the first week of
acclimatization and no animals were in estrus. All animals were
anticipated to have had some traveling experience, this was
supported by a lack of any evasive behavior and minimal time
taken (<3 seconds) when loading each horse onto the truck (22).
Throughout the study, horses were stabled in individual boxes
with at least 1 h of paddock access each day with members of the
same transport group. This grouping was maintained for 5 days
prior and 5 days post transportation.
Sample Collection
Serum samples in plain Vacutainer (BD, USA) were collected
prior to transport, at 12-24 h and 2 weeks after transport and were
stored at -20◦C until required.
Nasal swabs were collected prior to loading the horses onto the
truck, at unloading following the journey, and at 1 day and 5 days
after transport. Both nostrils of each horse were sampled, and
the swab was transferred to saline medium within a sterile 5mL
screwcap container. Aliquots of these samples were transported
to the University of Melbourne laboratory and stored at -80◦C.
Clinical examination was performed on each horse prior
to and 5 days after transport. Horses were examined for
subclinical respiratory disease through basic clinical examination
of the respiratory tract complemented by endoscopy of the
upper respiratory tract and tracheal wash (TW) collection as
described previously (23). Cytological analysis of TW aspirates
was performed using modified methods from Tee et al. (24).
TW smears were stained using Wright-Giemsa stain (Hema-tek
stain pack, Sigma-Aldrich Pty Ltd, Australia) and an average of
four differential cell counts on 100 cells using high-power (100X)
light microscopy was expressed as a percentage. Those horses
with >70% neutrophilia on cytological examination of TW were
classified as having subclinical respiratory disease (n= 6).
All procedures were approved by the Animals Care and Ethics
Committee of Charles Sturt University (ACEC 14/037).
Detection of EHV-1 and EHV-4 Specific
Antibodies
Levels of EHV-1 and-4 antibodies present before and 2
weeks after transport were determined using an ELISA that
differentiates specific antibodies using the variable amino acid
regions of glycoprotein G (gG) specific to each virus. This
is consistent with the standard timeframe to detect antibody
Frontiers in Veterinary Science | www.frontiersin.org 2 September 2018 | Volume 5 | Article 224
Muscat et al. Equine Transport and Changes in EHV Status
responses to herpes virus infection in horses (25). Glutathione-
s-transferase (GST) fusion proteins of EHV-1 gG and EHV-4 gG
were tested against each serum sample in triplicate. Likewise each
sample was tested against GST alone as a negative control, as
described previously (26). Antibody levels were considered to be
negative if the mean optical density of the 3 test wells was <0.1,
questionable if between 0.1 and 0.2, and positive if more than 0.2,
as has been validated in field studies (26, 27). Seroconversion in
the horses was defined as an increase in optical density of more
than 0.2 above the previous absorbance reading (27).
Detection of Viral Shedding by Quantitative
PCR (qPCR)
Nucleic acid was extracted from 200 µL of nasal swab
sample using an automated nucleic acid extraction system
(QIAxtractor, QIAGEN) and a QIAxtractor Vx kit according to
the manufacturer’s protocol. Quantitative PCR assays specific for
EHV-1,-2,-4, and-5 were performed using the GOTaq mastermix
system (Promega) according tomanufacturer’s instructions using
GO Taq Flexi Buffer, 1.5mMMgCl2, 200µM dNTP, 0.8µM Syto
9 (Life Technologies), 1U GO Taq Flexi DNA polymerase and
170 nM of each of the forward and reverse primers. Primers used
for detection of each of the viruses target the glycoprotein H
open reading frame (EHV-1 and EHV-5), the intergenic region
between ORF73 and 74 (EHV-4) or the glycoprotein B gene
(EHV-2) (8). Sizes of target amplicons for EHV-1,-2,-4 and-
5 were 86, 91, 167, and 87 base pairs respectively. The final
25 µL reaction volume included 2 µL of the extracted DNA
template. DNA extracted from cell cultures infected with EHV-
1 [strain EHV1.438/77 (28)], EHV-2 [strain EHV2.86/67 (29)],
EHV-4 [strain EHV4.405/76 (28)] and EHV-5 [strain EHV5.2-
141 (30)] were used as positive controls. Dilutions of nucleic
acid extracted from these reference virus cultures were included
on each plate along with nuclease free water as a negative
control. The qPCR was performed using the StratageneMx3000P
instrument. Thermocycling conditions were at 94◦C for 15min,
then 40 cycles of 94◦C for 15 sec, 60◦C annealing for 30 sec
and 72◦C extension for 30 sec. The melting curve analysis of
each amplicon was analyzed after one cycle of 95◦C for 1min,
55◦C for 30 sec and 95◦C for 30 sec. The fluorescence threshold
value used was the default value set by the analysis software.
Samples were considered positive if they had both (i) Cycle
quantification (Cq) values within the linear range of detection
of the dilution series of the positive controls, and (ii) a melting
temperature of the amplicon within 2 degrees of the positive
controls (31). To satisfy the first criteria the positive cut off value
for the EHV-1,-2,-4, and-5 specific assays were determined to
be 39.35, 37.4, 34.05, and 37.04 respectively. Efficiencies of the
qPCR assays for EHV-1,-2,-4, and-5 were 95, 102, 98 and 98%
respectively.
Virus Isolation
Virus isolation through cell culture was attempted on all
nasal swab samples. Briefly, the nasal swab infused saline
sample (500µL) was diluted with 1mL of maintenance
media (Dulbecco’s minimal essential medium (DMEM), 1%
v/v fetal bovine serum (FBS), 10mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 50µg/mL gentamicin,
5µg/mL amphoterin B, cotrimoxazole) and filtered through a
0.45µm syringe filter (29, 32). Vero and rabbit kidney (RK13)
cell lines are permissive and therefore selective for EHV-1 in
contrast to EHV-4 that only readily replicates in equine cells
(33). Semi-confluent monolayers of RK13, Vero, and equine
fetal kidney (EFK) cells in 12-well tissue culture plates were
inoculated with 200µL of filtrate. After 1 h adsorption at 37◦C,
5% v/v CO2 another 1mL of media was added and cell culture
plates were returned to incubator for daily observation for any
cytopathic effect (CPE). After 8 days of incubation, cell cultures
were passaged into new semi-confluent monolayers according
to qPCR results. Then 5ml of media was used to inoculate a
25 cm2 tissue culture flask with a mixture of RK13 or EFK cell
monolayers. Monolayers were examined for a further 2 days for
CPE.
EHV-2 DNA Sequencing
Nasal swabs positive on qPCR for EHV-2 were further
genotyped to assess possible transmission or recrudescence.
Primers targeting a portion of the glycoprotein B (gB) gene,
specifically nucleotides (nts) 33737–34138 of EHV-2 (GenBank
accession number NC_001650), were used for conventional
PCR amplification and direct sequencing of this 402 base
pair (bp) region for genotyping (34, 35). Template DNA (5
µL) generated by extraction from a positive nasal swab was
amplified in a 25 µL volume PCR reaction containing GO
Taq Flexi Buffer, 2mM MgCl2, 200µM dNTP mix, 0.8U GO
Taq Flexi DNA polymerase (Promega), 1.24µM of each of
the forward (5′-CAGTGTCTGCCAAGTTGATA-3′) and reverse
(5′-ATGGTCTCGATGTCAAACAC-3′) primers targeting the gB
gene, under the following conditions; an initial denature cycle
of 95◦C for 5min, 40 cycles of 95◦C for 30 sec, 60◦C for
30 sec, and 72◦C for 40 sec, and a final extension step of
72◦C for 5min. The PCR product was examined by agarose
gel electrophoresis with SYBR Green staining, products were
then gel purified (QIAquick, QIAGEN), and sequenced using
the forward amplification primer and big dye terminator version
3.1 chemistry (Applied Biosystems) according to manufacturer’s
instructions.
Amplicons unable to be sequenced directly were cloned
into a pGEMT vector (Promega) according to manufacturer’s
directions and transformed into E. coli JM109 cells. Plasmids
were purified from positive clones using Wizard Plus
SV Miniprep kit (Promega) according to manufacturer’s
instructions. One to three plasmid inserts per sample were
then sequenced, as described above, using the T7 primer
5′-TAATACGACTCACTATAGGG-3′.
Chromatograms were analyzed using Geneious version 6.1.2
software (Biomatters Ltd) (36). The nucleotide sequences of
EHV-2 reported in this study were submitted to GenBank
under the accession numbers MH351029-MH351081. Multiple
nucleotide sequence alignments were performed using CLUSTAL
W (35, 37). All sequences were compared to those of the
EHV-2 reference strain (strain 86/67, GenBank accession
number U20824.2) to determine percentage nucleotide identity.
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Phylogenetic relationships amongst the sequences were estimated
by the neighbor-joining (NJ) method (38, 39) using PHYML
version 2.2.0 (40) and the homologous gB region of an EHV-5
reference (EHV-5 2-141/67) strain (GenBank accession number
KM924295) as a designated outgroup. A bootstrap value >70%
represented efficient consensus support for determination of
groups (35, 41).
Further phylogenetic analysis against previously published
sequences of EHV-2 glycoprotein B (excluding non-functional
protein data) was performed to assess variability within this
portion of gB and confirm phylogenetic relationships. Only
sequences with full coverage of the gB region, specifically
nucleotides 1570 to 1971 (numbered according to complete
coding sequence of gB of EHV-2 strain ATCC, GenBank
accession no. HQ247755) were used [n = 26] which consisted
of 2 genome sequences (including EHV-2 reference strain),
10 complete and 14 partial coding sequences of EHV-2 gB.
Information on all sequences used for this analysis including
GenBank accession number, country where virus was isolated
and date collected (if known) can be found in Supplementary
Material (Table S1).
Data Analysis
Cycle quantification (Cq) data (number of amplification cycles
before fluorescence crosses threshold) from qPCR reactions were
analyzed using Genstat software 18th edition (VSN International,
Hemel Hampstead, UK). Data sets displayed normal distribution
upon visual inspection of Q-Q (quantile-quantile) plots. A two-
sided paired t-test was used for comparison of Cq values for each
virus prior to and post transport (for horses positive on qPCR for
a given virus pre and post transport), with a significant difference
in viral load defined when P < 0.05. An overall test between
pre and post transport was made (against the lowest Cq value or
most positive) after transport. Separate comparisons were made
between pre-transport Cq values and those at each time point
(Unloading, 1 day post, 5 days post transport). Any significant
findings were further assessed with a one sided test to confirm
either an increase or decrease in viral shedding. Viral strains
thought to have been reactivated from latent virus were defined
as those detectable only after transport and in one horse.
Odds ratios (OR) were calculated for analysis of any
association between viral infection (single or concurrent) and
subclinical respiratory disease. A significant association was
defined as an OR of more than 1 where the 95% confidence
interval did not include 1.
RESULTS
Serology
All horses were seronegative for EHV-1, however, the
seroprevalence for EHV-4 was 92% (11/12). Comparison of
antibody levels prior to and 2 weeks post transportation showed
no instances of seroconversion (increase in optical density> 0.2)
of EHV-1 or EHV-4 (Table S2).
Virus Detection and Shedding
There was a high prevalence of detection of EHV-2 (83%) and
EHV-5 (75%) amongst the horses (Table 1), where melt curve
analysis showed single peaks within temperature ranges of 78.95–
79.8◦C and 79.83–80.83◦C for EHV-2 and EHV-5 samples and
standards respectively. Raw Cq values for qPCR analysis are
shown in Figure 1. Prevalence of EHV-2 increased over time with
a total of 4 horses (Horses 3, 4, 9, 10) becoming positive after
transport. The EHV-2 viral load (as indicated by Cq value) was
significantly different pre-transport in comparison to lowest Cq
(i.e., most positive) values after transport (P = 0.007). The mean
difference in Cq between prior versus post was 4.9 (95%CI: 1.916,
7.898) and was confirmed to be an increase in shedding reflected
by a decrease in Cq (P = 0.003). However, no correlation was
found between a decrease in Cq and a particular time point after
transport.
The transportation event had no immediate effect on the
prevalence of EHV-5 detection. By 1 day post transport the
number of horses positive for the virus decreased by 17% [n =
2] (Table 1). No significant difference in EHV-5 viral load was
seen in association with transport overall or at any of the various
time points (Figure 1B).
All samples were negative for EHV-1 and EHV-4 by qPCR and
no CPE was detected after inoculation of nasal swabs onto cell
culture. The lack of CPE after 10 days in culture despite detection
of EHV-2 and EHV-5 DNA by qPCR is consistent with the slow
replication of these viruses in cell culture (6, 42).
A region of the gB gene of EHV-2 was sequenced for 27 of
the qPCR positive nasal samples from 10 horses. No sequence
could be obtained for 9 of the 36 qPCR-positive samples. Forty
seven sequences were returned from these samples and had 87.6–
99.3% nt identity to the reference strain. Of these, 14 sequences
shared 100% similarity with at least one other sequence isolated
in the study. Genomic variability of the targeted region of gB
amongst EHV-2 sequences isolated from the study and those
retrieved from GenBank ranged from 0–13.9% (i.e., 86.1–100%
nt identity) in comparison to the homologous gB portion of
the EHV-5 outgroup (EHV-5 2-141/67) that shared 75.6–81.3%
sequence similarity across all EHV-2 sequences. A neighbor-
joining phylogenetic tree including all EHV-2 sequences isolated
from the study and those obtained from GenBank can be found
in Supplementary Material (Figure S1).
Multiple EHV-2 sequences were detected in seven horses over
time or across replicates from the same sample. Horses 2, 5,
6, 7 appeared to be infected with multiple strains of EHV-2,
nucleotide and amino acid sequence variation is summarized
in Table 2. Nucleotide and amino acid alignments of sequences
TABLE 1 | Detection of gammaherpesviruses by qPCR in nasal swabs expressed
as a percentage of study population (n = 12) at various time points in the
transportation study.
Prior Unloading 1 day post 5 days post
EHV-2 58 75 83 83
EHV-5 75 75 58 58
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FIGURE 1 | Scatter plots showing Cq values from EHV-2 (A) and EHV-5 (B) qPCR of nasal samples collected from each horse prior to transport (+), at unloading (X),
1 day post transport (©), and 5 days post transport ().
within each horse are provided in Supplementary Material
(Data Sheets S1–S4). Figure 2 shows unrooted phylogenetic
trees highlighting the genetic heterogeneity of strains within
horses 2, 5, 6, and 7 and comparison against the reference strain.
Figure 3 displays a rooted phylogenetic tree of 34 EHV-
2 sequences isolated within the study, with the inclusion of
reference EHV-2 (EHV2.86/67) and EHV-5 outgroup (EHV5.2-
141) strains. The majority of the sequences (n=31) isolated
in this study were clustered closely together along with
the reference EHV-2 strain (Figure 3). This cluster included
sequences isolated from three horses that were negative for EHV-
2 prior to transport. Post transport sequences from these horses
(highlighted in red in Figure 3) shared either identical or highly
similar nucleotide sequences with isolates from other horses
involved in the transport event. Sequences from horse 12 and
a sequence from horse 5 isolated 1 day after transport were
genetically distant from each other and all other isolates from the
study (Figure 3).
Subclinical Disease
There were no observed signs of overt clinical respiratory
disease (i.e., pneumonia) in any of the horses studied. However,
half of the horses had persistent neutrophilic airway infiltrates
(>70% neutrophil content) in samples collected 5 days after
transportation, indicative of subclinical upper respiratory tract
disease. The remaining six horses all had normal tracheal wash
cytology. No association was observed between infection with
either of the gammaherpesviruses prior to or post transport
and incidence of subclinical upper respiratory tract disease
(Table S3).
DISCUSSION
This study investigated the effects of transport on shedding of
equid gammaherpesviruses and showed the shedding of EHV-
2 increased significantly after transport, while no such pattern
could be detected with EHV-5. Concurrent infections with
multiple strains of EHV-2 was common within the horses and
similarity of EHV-2 sequences across several horses suggested
high levels of transmission. No association was found between
gammaherpesvirus detection and the occurrence of subclinical
transport associated respiratory disease. In addition, no evidence
for reactivation of either EHV-1 or EHV-4 could be detected in
association with the transport event.
Clinical signs of transport pneumonia can take 5 days or
more to develop (43) hence a timeline to include the potential to
observe clinical disease was included in the study of these horses’
response to the transport event. Sample collection immediately
and 1 day after transport allows for the detection of more
immediate or acute responses to the transport event.
The detection of shedding of gammaherpesviruses in horses
both before and after transport reflects the ubiquity of these
viruses in horse populations (Table 1). Differences in the
Frontiers in Veterinary Science | www.frontiersin.org 5 September 2018 | Volume 5 | Article 224
Muscat et al. Equine Transport and Changes in EHV Status
FIGURE 2 | Unrooted phylogenetic trees comparing EHV-2 reference strain 86/87 and multiple strain types within individual horses 2 (A), 5 (B), 6 (C), 7 (D).
Sequences are labeled according to Horse (H-), time point of sample taken (Pre Transport [-P], Unloading [-U], 1 day post transport [-1D], 5 days post transport [-5D])
and clone (c-) number if more than one sequence was isolated from each sample. Scale bars represent substitutions per site.
temporal shedding patterns between EHV-2 and EHV-5 could
be consistent with a previous suggestion that reactivation of
these viruses may be triggered by different biological stimuli
(44). Results from a concurrent study confirmed that all horses
experienced stress in relation to the transport event as shown
by an increase in frequency of stress-inducing behaviors during
transport and elevated cortisol levels in serum after transport
(45). For horses positive for EHV-2 prior to transport, shedding
significantly increased after the transport event, however, there
was no association between a particular time point after transport
and change in viral load. Six out of eleven horses positive for
EHV-2 had highest viral load 5 days after transport according
to the raw Cq data (Figure 1A) thus a significant increase in
shedding was expected by this time. However, three of those six
horses were negative for EHV-2 prior to transport. Since the t-test
examines for any significant difference between 2 measurements
(i.e., viral load prior and post transport) these horses could
therefore not be included in the statistical analysis. The p-value
for the comparison between viral loads prior to transport and 5
days approached significance (P = 0.06), hence a larger sample
size may allow clarification of shedding patterns. Consideration
must also be given to the possibility of concurrent infections,
as up to 5 distinct EHV-2 isolates were isolated from one horse
(35, 46). Similarly, genetic variation of multiple EHV-2 sequences
obtained from individual horses in the current study suggests
co-infection of multiple strains (Figure 2). This can complicate
interpretation of the change in Cq which may not represent a
change in viral load of a particular isolate.
The detection of multiple sequence types in different horses
has previously been used to illustrate co-infection and re-
infection of individual horses with multiple genotypes (35, 46).
Using a similar approach in this study, the sequence types
detected in the horses before and after transport shared 96.8%
nucleotide identity and were also highly similar or identical to
the sequenced region of the well characterized EHV-2 strain
EHV2.86/67 (29). Horse 5 showed a uniform sequence type
across all samples (pre, unloading and day 5), while the day 1
sample showed a different EHV-2 sequence with 18 SNPs and
3 amino acid changes compared to the other samples from the
same horse (Table 2). This finding of a distinct virus in the
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FIGURE 3 | Neighbor joining phylogenetic tree illustrating relationships
amongst sequences obtained from study, reference EHV-2 87/67 strain
(GenBank accession number U20824.2) and outgroup EHV-5 Strain 2-141/67
(GenBank accession number KM924295). Sequences are labeled according
to Horse (H-), time point of sample taken [Pre Transport [-P], Unloading [-U], 1
day post transport [-1D], 5 days post transport [-5D]] and clone (c-) number if
more than one isolate was sequenced from each sample. Tip labels
highlighted in red denote sequences obtained from horses positive for EHV-2
only after transport, tip labels in blue denote sequences that may have
originated from reactivated virus. Scale bar represents substitutions per site.
series from a single horse may represent a new infection or
recrudescence of a distinct sequence type over the course of
the study. It is important to consider that recombination events
can occur frequently between herpesviruses which in turn could
impact viral sequence analysis (47). No sequence types entirely
identical to that isolated from horse 5 1 day after transport were
detected in the other horses (Figure 3) and therefore the origin
of this virus, namely by reactivation of latent virus or re-infection
from the other horses cannot be conclusively determined.
Identical or highly similar EHV-2 gB sequences isolated from
nasal samples of different horses in the study (Figure 3) is
consistent with shedding and horizontal transmission of EHV-
2. Horses were provided with the opportunity to socialize in
yards each day for 1 h allowing for exposure outside of the
transport event. Phylogenetic analysis suggests that identical
viral strains were detected in multiple horses that were on
separate vehicles (Figure 3). Three out of four horses that became
positive for EHV-2 after transport (horse numbers 3, 4, and
9) shared at least 98.1% nt identity and grouped with other
isolates. As is the case with Horse 2, the notable increase in
shedding over time from unloading to 5 days post transport
likely represents cases of primary exposure and not reactivation
of latent virus. By comparison, reactivated EHV-1 produces a
relatively low viral load and shorter periods of shedding after
induced reactivation from transport stress or administration of
corticosteroids compared with an infection event (19, 21).
TABLE 2 | Genetic variation of EHV-2 sequences isolated from 4 individual
horses, displayed as number of changes compared with the consensus sequence
within each horse.
Horse Time point Number of changes in EHV-2 gB amplicon
SNPs Amino acid
2 Pre 0 0
Unloading 0 0
1 day post 0 0
5 days post 8 2
5 Pre 0 0
Unloading 0 0
1 day post (c1) 18 3
1 day post (c2) 2 0
5 days post 0 0
6 Pre (c1) 3 2
Pre (c2) 1 0
Unloading (c1) 4 0
Unloading (c2) 3 0
1 day post 3 0
5 days post 7 0
7 Pre (c1) 4 0
Pre (c2) 5 1
Pre (c3) 3 0
Unloading 6 0
1 day post 4 0
5 days post (c1) 5 0
5 days post (c2) 7 1
Seroprevelance of EHV-4 within the study population appears
to be in accordance with previous research however the lack
of seropositivity to EHV-1 in any of the horses is notable
considering that exposure to EHV-1 most likely occurs early in
the animal’s life (27, 48). No seroconversion or nasal shedding
of EHV-1/-4 after transport was detected. This reflects similar
findings to that of Pusterla et al. (21) who investigated prevalence
of EHV-1 nasal shedding and viremia in 302 adult horses that had
undergone air transportation followed by an 8–10 day journey
in a trailer. Despite exposure to a more intensive transport
event only 1% (n = 3) of the horses shed detectable levels of
EHV-1. These horses displayed no clinical signs and typically
low viral copies in nasopharyngeal secretions, hence were an
unlikely source of infection for other horses (49). Interestingly,
shedding of EHV-4 at a sales event in South Africa was detected
by qPCR within nasal secretions of 14% [n = 13] of 2 year
old Thoroughbreds and most of these horses [n = 12] were
seropositive to EHV-4 (50). In comparison to these horses,
detection of EHV-4 nasal shedding in one horse was likely a
result of a recent primary EHV-4 infection as there was a lack
of a detectable antibody response. Similarly, no seroconversion
was recorded. The timeframe for seroconversion to equid
herpesviruses after reactivation is uncertain, hence it is possible
this could have occurred after the 2 week post-transport sample
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point of the current study. Fecal glucocorticoid metabolite
concentrations were analyzed as physiological indicators of stress
and were predominantly associated with longer travel duration
and days post arrival (50). The elevated levels of EHV-4 shedding
in the South African study may be due to the younger age of the
horses or the length of the transport in the South African study
in comparison to the 8-h event and relatively older age of horses
in the current study.
The absence of any relationship between viral infection and
occurrence of subclinical disease is also consistent with the
literature, since gammaherpesviruses are frequently detected in
healthy hosts (35). Further, horse 5 which appears to have
been shedding a reactivated EHV-2 virus was classed in the
sub-clinically normal group. The increase in shedding of EHV-
2 after transport partially supports this hypothesis, however
the likelihood of transport-related reactivation of latent equine
herpesviruses remains questionable from the data. Further,
this study showed no detection of alphaherpesvirus shedding
in the transported horses and no evidence of any clinical
implications of increased shedding or recrudescence of EHV-
2 after transport. However, genes have been identified in both
EHV-2 and EHV-5 that produce homologues of G protein
coupled receptors (GPCRs) and molecules such as interleukin
(IL-) 10 that have immunomodulatory effects in other hosts (9–
11, 51). Furthermore concurrent EHV-2 infection may play a role
in reactivation of latent EHV-1 infections (52) and predisposing
foals to Rhodococcus equi infection (53).
This study has shown that detection of EHV-2 and EHV-5
viral infection in horses is likely to increase with transportation
due to stress-associated reactivation of latent infections or
increased shedding in actively infected hosts. This shedding
may also increase the opportunity for horizontal transmission
in the closed airspace of the transport vehicle or subsequently
after transport. This potential increase in spread of infectious
agents, such as EHV, may have important implications for
controlling and preventing transmission of pathogens from
the transported horse, such as the time interval before such
horses are integrated with others in active training or for
breeding purposes. The ubiquitous nature of these viruses and
their ability to concurrently infect horses makes interpretation
of shedding patterns difficult. No direct association between
sub-clinical respiratory disease and gammaherpesvirus infection
was detected. Nevertheless to reduce the risk of infection and
transmission of respiratory pathogens, stringent biosecurity
measures should continue to be in place whenever horses are
transported.
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